{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:47Z","timestamp":1791685367338,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10587-z","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:27:49Z","timestamp":1748132869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nobiletin potentially reduce lipid accumulation by up-regulating the SIRT1-AMPK signaling pathway in HepG2 hepatocarcinoma cells"],"prefix":"10.1007","volume":"52","author":[{"given":"Hajar","family":"Shokri-Afra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Yousefi Abdolmaleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-2046","authenticated-orcid":false,"given":"Elnaz Sadat","family":"Mousavi Sadr Jadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziaeddin","family":"Oladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemen","family":"Moradi-Sardareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Nabi Afjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davod","family":"Ilbeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Barmaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"issue":"4","key":"10587_CR1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801","journal-title":"J Hepatol"},{"issue":"3","key":"10587_CR2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","volume":"48","author":"AL Fracanzani","year":"2008","unstructured":"Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48(3):792\u2013798","journal-title":"Hepatology"},{"issue":"1","key":"10587_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384","journal-title":"Hepatology"},{"issue":"3","key":"10587_CR4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X11430859","volume":"5","author":"JM Kneeman","year":"2012","unstructured":"Kneeman JM, Misdraji J, Corey KE (2012) Secondary causes of nonalcoholic fatty liver disease. Ther Adv Gastroenterol 5(3):199\u2013207","journal-title":"Ther Adv Gastroenterol"},{"issue":"2","key":"10587_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1751-2980.2008.00323.x","volume":"9","author":"JG Fan","year":"2008","unstructured":"Fan JG (2008) Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis 9(2):63\u201367","journal-title":"J Dig Dis"},{"issue":"3","key":"10587_CR6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.clinthera.2021.01.022","volume":"43","author":"AS Barritt","year":"2021","unstructured":"Barritt AS (2021) Nonalcoholic fatty liver disease: epidemiology, assessments, and interventions entering 2021. Clin Ther 43(3):436\u2013437","journal-title":"Clin Ther"},{"issue":"1","key":"10587_CR7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328\u2013357","journal-title":"Hepatology"},{"issue":"2","key":"10587_CR8","first-page":"1","volume":"27","author":"P Anggreini","year":"2023","unstructured":"Anggreini P, Kuncoro H, Sumiwi SA, Levita J (2023) Role of the AMPK\/SIRT1 pathway in non-alcoholic fatty liver disease. Mol Med Rep 27(2):1\u201311","journal-title":"Mol Med Rep"},{"issue":"4","key":"10587_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2008.08.014","volume":"8","author":"AS Banks","year":"2008","unstructured":"Banks AS, Kon N, Knight C, Matsumoto M, Guti\u00e9rrez-Ju\u00e1rez R, Rossetti L, Gu W, Accili D (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8(4):333\u2013341","journal-title":"Cell Metab"},{"issue":"4","key":"10587_CR10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","volume":"9","author":"A Purushotham","year":"2009","unstructured":"Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9(4):327\u2013338","journal-title":"Cell Metab"},{"issue":"46","key":"10587_CR11","doi-asserted-by":"crossref","first-page":"47898","DOI":"10.1074\/jbc.M408149200","volume":"279","author":"M Zang","year":"2004","unstructured":"Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA (2004) AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279(46):47898\u201347905","journal-title":"J Biol Chem"},{"issue":"8","key":"10587_CR12","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.2337\/db05-1188","volume":"55","author":"M Zang","year":"2006","unstructured":"Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor\u2013deficient mice. Diabetes 55(8):2180\u20132191","journal-title":"Diabetes"},{"key":"10587_CR13","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Qian Q, Ying N, Lai J, Feng L, Zheng S, Jiang F, Song Q, Chai H, Dou X (2020) Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice. Front Pharmacol 11:560905","journal-title":"Front Pharmacol"},{"issue":"6","key":"10587_CR14","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1745-7254.2008.00807.x","volume":"29","author":"J Shang","year":"2008","unstructured":"Shang J (2008) Chen L-l, Xiao F-x, Sun H, Ding H-c, Xiao H: Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29(6):698\u2013706","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"10587_CR15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","volume":"127","author":"M Lagouge","year":"2006","unstructured":"Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1\u03b1. Cell 127(6):1109\u20131122","journal-title":"Cell"},{"issue":"1","key":"10587_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20070140","volume":"404","author":"S Michan","year":"2007","unstructured":"Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404(1):1\u201313","journal-title":"Biochem J"},{"issue":"4","key":"10587_CR17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10408398.2014.952399","volume":"57","author":"B Van De Wier","year":"2017","unstructured":"Van De Wier B, Koek GH, Bast A, Haenen GR (2017) The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr 57(4):834\u2013855","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"5","key":"10587_CR18","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10787-022-01054-3","volume":"30","author":"H Zalpoor","year":"2022","unstructured":"Zalpoor H, Bakhtiyari M, Shapourian H, Rostampour P, Tavakol C, Nabi-Afjadi M (2022) Hesperetin as an anti-SARS-CoV-2 agent can inhibit COVID-19-associated cancer progression by suppressing intracellular signaling pathways. Inflammopharmacology 30(5):1533\u20131539","journal-title":"Inflammopharmacology"},{"issue":"4","key":"10587_CR19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124837","volume":"10","author":"M Kilic Eren","year":"2015","unstructured":"Kilic Eren M, Kilincli A, Eren \u00d6 (2015) Resveratrol induced premature senescence is associated with DNA damage mediated SIRT1 and SIRT2 down-regulation. PLoS ONE 10(4):e0124837","journal-title":"PLoS ONE"},{"issue":"4","key":"10587_CR20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3945\/ajcn.111.028894","volume":"95","author":"NM Wedick","year":"2012","unstructured":"Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, Rosner B, Willett W, Hu FB, Sun Q, van Dam RM (2012) Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr 95(4):925\u2013933","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10587_CR21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.foodchem.2008.02.068","volume":"110","author":"B Sharma","year":"2008","unstructured":"Sharma B, Viswanath G, Salunke R, Roy P (2008) Effects of flavonoid-rich extract from seeds of Eugenia jambolana (L.) on carbohydrate and lipid metabolism in diabetic mice. Food Chem 110(3):697\u2013705","journal-title":"Food Chem"},{"issue":"1","key":"10587_CR22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOL.0b013e32835c07fd","volume":"24","author":"JM Assini","year":"2013","unstructured":"Assini JM, Mulvihill EE, Huff MW (2013) Citrus flavonoids and lipid metabolism. Curr Opin Lipidol 24(1):34\u201340","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"10587_CR23","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2337\/db09-0634","volume":"58","author":"EE Mulvihill","year":"2009","unstructured":"Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW (2009) Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor\u2013null mice with diet-induced insulin resistance. Diabetes 58(10):2198\u20132210","journal-title":"Diabetes"},{"issue":"5","key":"10587_CR24","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/db10-0589","volume":"60","author":"EE Mulvihill","year":"2011","unstructured":"Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A (2011) Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes 60(5):1446\u20131457","journal-title":"Diabetes"},{"issue":"5","key":"10587_CR25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/bi026731o","volume":"42","author":"NM Borradaile","year":"2003","unstructured":"Borradaile NM, de Dreu LE, Barrett PHR, Behrsin CD, Huff MW (2003) Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 42(5):1283\u20131291","journal-title":"Biochemistry"},{"issue":"9","key":"10587_CR26","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1194\/jlr.M200115-JLR200","volume":"43","author":"NM Borradaile","year":"2002","unstructured":"Borradaile NM, de Dreu LE, Barrett PHR, Huff MW (2002) Inhibition of hepatocyte apoB secretion by naringenin. J Lipid Res 43(9):1544\u20131554","journal-title":"J Lipid Res"},{"issue":"4","key":"10587_CR27","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3892\/etm.2016.3069","volume":"11","author":"MJ Alkhatatbeh","year":"2016","unstructured":"Alkhatatbeh MJ, Lincz LF, Thorne RF (2016) Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease. Exp Ther Med 11(4):1487\u20131492","journal-title":"Exp Ther Med"},{"key":"10587_CR28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13105-019-00678-4","volume":"75","author":"H Shokri Afra","year":"2019","unstructured":"Shokri Afra H, Zangooei M, Meshkani R, Ghahremani MH, Ilbeigi D, Khedri A, Shahmohamadnejad S, Khaghani S, Nourbakhsh M (2019) Hesperetin is a potent bioactivator that activates SIRT1-AMPK signaling pathway in HepG2 cells. J Physiol Biochem 75:125\u2013133","journal-title":"J Physiol Biochem"},{"issue":"Suppl 1","key":"10587_CR29","first-page":"125","volume":"22","author":"D Ilbeigi","year":"2020","unstructured":"Ilbeigi D, Nourbakhsh M, Pasalar P, Meshkani R, Afra HS, Panahi G, Borji M, Sharifi R (2020) Nicotinamide phosphoribosyltransferase knockdown leads to lipid accumulation in HepG2 cells through the SIRT1-AMPK pathway. Cell J (Yakhteh) 22(Suppl 1):125","journal-title":"Cell J (Yakhteh)"},{"issue":"35","key":"10587_CR30","doi-asserted-by":"crossref","first-page":"22448","DOI":"10.1039\/D2RA00486K","volume":"12","author":"MA Said","year":"2022","unstructured":"Said MA, Albohy A, Abdelrahman MA, Ibarhim HS (2022) Remdesivir analog as SARS-CoV-2 polymerase inhibitor: virtual screening of a database generated by scaffold replacement. RSC Adv 12(35):22448\u201322457","journal-title":"RSC Adv"},{"issue":"12","key":"10587_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293185","volume":"18","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Alhumaydhi FA, Alsayari A, Sharaf SE, Shafi S, Anwar S, Shahwan M, Atiya A, Shamsi A (2023) Targeting Sirtuin 1 for therapeutic potential: Drug repurposing approach integrating docking and molecular dynamics simulations. PLoS ONE 18(12):e0293185","journal-title":"PLoS ONE"},{"issue":"8","key":"10587_CR32","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.bbapap.2009.10.025","volume":"1804","author":"JA Baur","year":"2010","unstructured":"Baur JA (2010) Biochemical effects of SIRT1 activators. Biochim Biophys Acta (BBA) Proteins Proteomics 1804(8):1626\u20131634","journal-title":"Biochim Biophys Acta (BBA) Proteins Proteomics"},{"issue":"11","key":"10587_CR33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrm.2016.93","volume":"17","author":"MS Bonkowski","year":"2016","unstructured":"Bonkowski MS, Sinclair DA (2016) Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol 17(11):679\u2013690","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10587_CR34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tips.2013.12.004","volume":"35","author":"BP Hubbard","year":"2014","unstructured":"Hubbard BP, Sinclair DA (2014) Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 35(3):146\u2013154","journal-title":"Trends Pharmacol Sci"},{"issue":"6954","key":"10587_CR35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature01960","volume":"425","author":"KT Howitz","year":"2003","unstructured":"Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang L-L (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954):191\u2013196","journal-title":"Nature"},{"issue":"1","key":"10587_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.abb.2010.05.003","volume":"501","author":"S Chung","year":"2010","unstructured":"Chung S, Yao H, Caito S (2010) Hwang J-w, Arunachalam G, Rahman I: regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 501(1):79\u201390","journal-title":"Arch Biochem Biophys"},{"issue":"14","key":"10587_CR37","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.3390\/molecules25143287","volume":"25","author":"B Karaman Mayack","year":"2020","unstructured":"Karaman Mayack B, Sippl W, Ntie-Kang F (2020) Natural products as modulators of sirtuins. Molecules 25(14):3287","journal-title":"Molecules"},{"key":"10587_CR38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01225","volume":"11","author":"C Iside","year":"2020","unstructured":"Iside C, Scafuro M, Nebbioso A, Altucci L (2020) SIRT1 activation by natural phytochemicals: an overview. Front Pharmacol 11:551744","journal-title":"Front Pharmacol"},{"issue":"4","key":"10587_CR39","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/ijms21041250","volume":"21","author":"M Leri","year":"2020","unstructured":"Leri M, Scuto M, Ontario ML, Calabrese V, Calabrese EJ, Bucciantini M, Stefani M (2020) Healthy effects of plant polyphenols: molecular mechanisms. Int J Mol Sci 21(4):1250","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10587_CR40","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.bbadis.2013.08.010","volume":"1832","author":"MD Sanchez-Ni\u00f1o","year":"2013","unstructured":"Sanchez-Ni\u00f1o MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, Burkly LC, Nair V, Kretzler M, Hodgin JB (2013) Fn14 in podocytes and proteinuric kidney disease. Biochim et Biophys Acta (BBA) Mol Basis Dis 1832(12):2232\u20132243","journal-title":"Biochim et Biophys Acta (BBA) Mol Basis Dis"},{"issue":"8","key":"10587_CR41","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jnutbio.2015.03.002","volume":"26","author":"K Yang","year":"2015","unstructured":"Yang K, Hashemi Z, Han W, Jin A, Yang H, Ozga J, Li L, Chan CB (2015) Hydrolysis enhances bioavailability of proanthocyanidin-derived metabolites and improves \u03b2-cell function in glucose intolerant rats. J Nutr Biochem 26(8):850\u2013859","journal-title":"J Nutr Biochem"},{"key":"10587_CR42","volume":"915","author":"J-J Li","year":"2022","unstructured":"Li J-J, Jiang H-C, Wang A, Bu F-T, Jia P-C, Zhu S, Zhu L, Huang C, Li J (2022) Hesperetin derivative-16 attenuates CCl4-induced inflammation and liver fibrosis by activating AMPK\/SIRT3 pathway. Eur J Pharmacol 915:174530","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10587_CR43","first-page":"5815","volume":"18","author":"Z Peng","year":"2018","unstructured":"Peng Z, Li X, Xing D, Du X, Wang Z, Liu G, Li X (2018) Nobiletin alleviates palmitic acid-induced NLRP3 inflammasome activation in a sirtuin 1-dependent manner in AML-12 cells. Mol Med Rep 18(6):5815\u20135822","journal-title":"Mol Med Rep"},{"key":"10587_CR44","first-page":"549","volume":"6","author":"G Qi","year":"1863","unstructured":"Qi G, Guo R, Tian H, Li L, Liu H, Mi Y (1863) Liu X (2018) Nobiletin protects against insulin resistance and disorders of lipid metabolism by reprogramming of circadian clock in hepatocytes. Biochim Biophys Acta (BBA) Mol Cell Biol 6:549\u2013562","journal-title":"Biochim Biophys Acta (BBA) Mol Cell Biol"},{"issue":"3","key":"10587_CR45","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/fsn3.953","volume":"7","author":"GD Zheng","year":"2019","unstructured":"Zheng GD, Hu PJ, Chao YX, Zhou Y, Yang XJ, Chen BZ, Yu XY, Cai Y (2019) Nobiletin induces growth inhibition and apoptosis in human nasopharyngeal carcinoma C666\u20131 cells through regulating PARP-2\/SIRT 1\/AMPK signaling pathway. Food Sci Nutr 7(3):1104\u20131112","journal-title":"Food Sci Nutr"},{"issue":"1","key":"10587_CR46","doi-asserted-by":"crossref","first-page":"7420265","DOI":"10.1155\/2018\/7420265","volume":"2018","author":"T Yuk","year":"2018","unstructured":"Yuk T, Kim Y, Yang J, Sung J, Jeong HS, Lee J (2018) Nobiletin inhibits hepatic lipogenesis via activation of AMP-activated protein kinase. Evid Based Complem Alternat Med 2018(1):7420265","journal-title":"Evid Based Complem Alternat Med"},{"issue":"24","key":"10587_CR47","doi-asserted-by":"crossref","first-page":"12843","DOI":"10.1021\/jf2033208","volume":"59","author":"Y Choi","year":"2011","unstructured":"Choi Y, Kim Y, Ham H, Park Y, Jeong H-S, Lee J (2011) Nobiletin suppresses adipogenesis by regulating the expression of adipogenic transcription factors and the activation of AMP-activated protein kinase (AMPK). J Agric Food Chem 59(24):12843\u201312849","journal-title":"J Agric Food Chem"},{"issue":"30","key":"10587_CR48","doi-asserted-by":"crossref","first-page":"E2772","DOI":"10.1073\/pnas.1303628110","volume":"110","author":"M Gertz","year":"2013","unstructured":"Gertz M, Fischer F, Nguyen GTT, Lakshminarasimhan M, Schutkowski M, Weyand M, Steegborn C (2013) Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc Natl Acad Sci USA 110(30):E2772\u2013E2781","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10587_CR49","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/db13-0368","volume":"62","author":"DG Hardie","year":"2013","unstructured":"Hardie DG (2013) AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62(7):2164\u20132172","journal-title":"Diabetes"},{"key":"10587_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-016-0392-3","volume":"16","author":"L-F Wang","year":"2017","unstructured":"Wang L-F, Wang X-N, Huang C-C, Hu L, Xiao Y-F, Guan X-H, Qian Y-S, Deng K-Y, Xin H-B (2017) Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1\/AMPK\u03b1\/SREBP1 signaling pathway. Lipids Health Dis 16:1\u201313","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10587_CR51","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41598-017-02416-6","volume":"7","author":"A Yoo","year":"2017","unstructured":"Yoo A, Narayan VP, Hong EY, Whang WK, Park T (2017) Scopolin ameliorates high-fat diet induced hepatic steatosis in mice: potential involvement of SIRT1-mediated signaling cascades in the liver. Sci Rep 7(1):2251","journal-title":"Sci Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10587-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10587-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10587-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:31:32Z","timestamp":1766853092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10587-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10587"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10587-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"There is no competing interest to be declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"503"}}